NASDAQ:KROS Keros Therapeutics (KROS) Stock Forecast, Price & News $43.89 -5.07 (-10.36%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$42.23▼$47.6250-Day Range$37.26▼$51.0152-Week Range$24.38▼$59.96Volume1.13 million shsAverage Volume174,921 shsMarket Capitalization$1.30 billionP/E RatioN/ADividend YieldN/APrice Target$103.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Keros Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside136.4% Upside$103.75 Price TargetShort InterestHealthy3.34% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.90Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.44) to ($5.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.37 out of 5 starsMedical Sector189th out of 988 stocksPharmaceutical Preparations Industry80th out of 479 stocks 3.5 Analyst's Opinion Consensus RatingKeros Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $103.75, Keros Therapeutics has a forecasted upside of 136.4% from its current price of $43.89.Amount of Analyst CoverageKeros Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.34% of the float of Keros Therapeutics has been sold short.Short Interest Ratio / Days to CoverKeros Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Keros Therapeutics has recently increased by 12.00%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKeros Therapeutics does not currently pay a dividend.Dividend GrowthKeros Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KROS. Previous Next 3.3 News and Social Media Coverage News SentimentKeros Therapeutics has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Keros Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Keros Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Keros Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders28.00% of the stock of Keros Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.14% of the stock of Keros Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Keros Therapeutics are expected to grow in the coming year, from ($5.44) to ($5.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Keros Therapeutics is -9.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Keros Therapeutics is -9.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKeros Therapeutics has a P/B Ratio of 4.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Keros Therapeutics (NASDAQ:KROS) StockKeros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Read More Receive KROS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KROS Stock News HeadlinesJune 9, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Keros Therapeutics (KROS)June 9, 2023 | finance.yahoo.comKeros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual Congress of the European Hematology AssociationJune 10, 2023 | Behind the Markets (Ad)AI Creates New Cancer Drug - In Just 30 Days!On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...June 7, 2023 | finance.yahoo.comKeros Therapeutics to Present at Goldman Sach’s 44th Annual Global Healthcare ConferenceMay 29, 2023 | markets.businessinsider.comKeros Therapeutics (KROS) Receives a Rating Update from a Top AnalystMay 23, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Rain Therapeutics (RAIN) and Keros Therapeutics (KROS)May 22, 2023 | finance.yahoo.comKeros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International ConferenceMay 11, 2023 | finance.yahoo.comKeros Therapeutics to Present at the 28th Annual Congress of the European Hematology AssociationJune 10, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 10, 2023 | americanbankingnews.comHC Wainwright Comments on Keros Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:KROS)May 9, 2023 | msn.comHC Wainwright & Co. Reiterates Keros Therapeutics (KROS) Buy RecommendationMay 8, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Karuna Therapeutics (KRTX) and Keros Therapeutics (KROS)May 7, 2023 | seekingalpha.comKeros Therapeutics GAAP EPS of -$1.26May 7, 2023 | americanbankingnews.comPiper Sandler Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $110.00May 7, 2023 | americanbankingnews.comKeros Therapeutics, Inc. (NASDAQ:KROS) Given Average Recommendation of "Buy" by AnalystsMay 6, 2023 | nasdaq.comPiper Sandler Maintains Keros Therapeutics (KROS) Overweight RecommendationMay 5, 2023 | finanznachrichten.deKeros Therapeutics, Inc.: Keros Therapeutics Reports Recent Business Highlights and First Quarter 2023 Financial ResultsMay 4, 2023 | msn.comRecap: Keros Therapeutics Q1 EarningsMay 4, 2023 | finance.yahoo.comKeros Therapeutics Reports Recent Business Highlights and First Quarter 2023 Financial ResultsMay 1, 2023 | americanbankingnews.comKeros Therapeutics, Inc. (NASDAQ:KROS) Short Interest UpdateApril 30, 2023 | seekingalpha.comKeros Therapeutics: Undercovered Company With Data From All ProgramsApril 22, 2023 | americanbankingnews.comKeros Therapeutics (NASDAQ:KROS) Trading 3.7% Higher April 19, 2023 | finance.yahoo.comKeros Therapeutics Appoints Alpna Seth, Ph.D., to its Board of DirectorsApril 18, 2023 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Keros Therapeutics (KROS)April 10, 2023 | americanbankingnews.comKeros Therapeutics, Inc. (NASDAQ:KROS) Receives $106.25 Consensus Price Target from AnalystsApril 2, 2023 | americanbankingnews.comShort Interest in Keros Therapeutics, Inc. (NASDAQ:KROS) Rises By 19.3%April 1, 2023 | americanbankingnews.comKeros Therapeutics (NASDAQ:KROS) Shares Down 3.8% See More Headlines KROS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KROS Company Calendar Last Earnings5/04/2023Today6/09/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KROS CUSIPN/A CIK1664710 Webwww.kerostx.com Phone617-314-6297FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Forecast$103.75 High Stock Price Forecast$110.00 Low Stock Price Forecast$100.00 Forecasted Upside/Downside+136.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($4.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-104,680,000.00 Net MarginsN/A Pretax Margin-399.51% Return on Equity-42.89% Return on Assets-39.74% Debt Debt-to-Equity RatioN/A Current Ratio23.43 Quick Ratio23.43 Sales & Book Value Annual Sales$20.10 million Price / Sales64.60 Cash FlowN/A Price / Cash FlowN/A Book Value$10.07 per share Price / Book4.36Miscellaneous Outstanding Shares29,584,000Free Float21,300,000Market Cap$1.30 billion OptionableNot Optionable Beta1.22 Key ExecutivesDr. Jasbir S. Seehra Ph.D. (Age 66)Pres, CEO, Treasurer, & Director Comp: $908.09kMr. Keith C. Regnante MBA (Age 52)Chief Financial Officer Comp: $603.24kDr. Jennifer Lachey Ph.D. (Age 49)Chief Scientific Officer Comp: $604.74kMr. Christopher Rovaldi M.Sc. (Age 48)Chief Operating Officer Ms. Esther Cho J.D.Head of Legal & Corp. Sec.Ms. Robin WagnerVP of HRDr. Simon Cooper MBBS (Age 52)Chief Medical Officer More ExecutivesKey CompetitorsTravere TherapeuticsNASDAQ:TVTXTaro Pharmaceutical IndustriesNYSE:TAROArcus BiosciencesNYSE:RCUSMoonLake ImmunotherapeuticsNASDAQ:MLTXIDEAYA BiosciencesNASDAQ:IDYAView All CompetitorsInsiders & InstitutionsPutnam Investments LLCSold 332 shares on 5/22/2023Ownership: 0.027%JPMorgan Chase & Co.Sold 18,061 shares on 5/18/2023Ownership: 0.079%New York State Common Retirement FundSold 2,985 shares on 5/18/2023Ownership: 0.034%First Light Asset Management LLCBought 1,552 shares on 5/16/2023Ownership: 2.008%AQR Capital Management LLCBought 7,591 shares on 5/16/2023Ownership: 0.026%View All Insider TransactionsView All Institutional Transactions KROS Stock - Frequently Asked Questions Should I buy or sell Keros Therapeutics stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Keros Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KROS shares. View KROS analyst ratings or view top-rated stocks. What is Keros Therapeutics' stock price forecast for 2023? 5 brokers have issued 12-month price targets for Keros Therapeutics' stock. Their KROS share price forecasts range from $100.00 to $110.00. On average, they expect the company's share price to reach $103.75 in the next year. This suggests a possible upside of 136.4% from the stock's current price. View analysts price targets for KROS or view top-rated stocks among Wall Street analysts. How have KROS shares performed in 2023? Keros Therapeutics' stock was trading at $48.02 on January 1st, 2023. Since then, KROS stock has decreased by 8.6% and is now trading at $43.89. View the best growth stocks for 2023 here. When is Keros Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our KROS earnings forecast. How were Keros Therapeutics' earnings last quarter? Keros Therapeutics, Inc. (NASDAQ:KROS) issued its quarterly earnings results on Thursday, May, 4th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.14) by $0.12. During the same quarter in the prior year, the business posted ($1.01) earnings per share. What ETFs hold Keros Therapeutics' stock? ETFs with the largest weight of Keros Therapeutics (NASDAQ:KROS) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), BlackRock Future Health ETF (BMED), iShares Micro-Cap ETF (IWC) and Invesco Nasdaq Biotechnology ETF (IBBQ). What other stocks do shareholders of Keros Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Keros Therapeutics investors own include AbbVie (ABBV), Brainstorm Cell Therapeutics (BCLI), Cloudera (CLDR), CVS Health (CVS), Inovio Pharmaceuticals (INO), Iovance Biotherapeutics (IOVA), Karyopharm Therapeutics (KPTI), Neurocrine Biosciences (NBIX), Novavax (NVAX) and Pfizer (PFE). When did Keros Therapeutics IPO? (KROS) raised $75 million in an initial public offering (IPO) on Wednesday, April 8th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager. What is Keros Therapeutics' stock symbol? Keros Therapeutics trades on the NASDAQ under the ticker symbol "KROS." Who are Keros Therapeutics' major shareholders? Keros Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (13.70%), BlackRock Inc. (5.67%), Price T Rowe Associates Inc. MD (3.90%), State Street Corp (3.19%), Candriam S.C.A. (2.52%) and First Light Asset Management LLC (2.01%). Insiders that own company stock include Christopher Rovaldi, Claudia Ordonez, Jennifer Lachey, Julius Knowles, Ran Nussbaum and Richard K Prins. View institutional ownership trends. How do I buy shares of Keros Therapeutics? Shares of KROS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Keros Therapeutics' stock price today? One share of KROS stock can currently be purchased for approximately $43.89. How much money does Keros Therapeutics make? Keros Therapeutics (NASDAQ:KROS) has a market capitalization of $1.30 billion and generates $20.10 million in revenue each year. The company earns $-104,680,000.00 in net income (profit) each year or ($4.40) on an earnings per share basis. How can I contact Keros Therapeutics? Keros Therapeutics' mailing address is 99 HAYDEN AVENUE SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER, LEXINGTON MA, 02421. The official website for the company is www.kerostx.com. The company can be reached via phone at 617-314-6297 or via email at jbalanova@troutgroup.com. This page (NASDAQ:KROS) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.